ANCC Adult-Gero Review Test 2026/2027

ANCC Adult-Gero Review Test 2026/2027
Acute cough - ANS-< 3 weeks
Subacute cough - ANS-3-8 weeks
Chronic cough - ANS->8 weeks
Acute Bronchitis - ANS-inflammation of the bronchioles
Acute bronchitis etiology - ANS-almost always viral
Acute Bronchitis symptoms - ANS-cough that usually lasts 10-20 days
Acute Bronchitis Treatment - ANS-OTC antitussive, NSAIDs, antibiotics NOT
recommended
Pneumonia etiology - ANS-*S. pneumoniae
*M. pneumoniae
*C. pneumoniae
Pneumonia treatment - ANS-*healthy with no recent antibiotics=macrolide or doxy
*comorbidities or recent antibiotic=DRSP=resp quinolone OR beta-lactam + macrolide
OR beta-lactam +Doxy
Pneumonia length of treatment - ANS-*minimum 5 days
*average 5-10 days
*re-evaluate after 48-72 hrs if poor response
Pneumovax - ANS-*PPSV: 19-64 with increased risk
*PCV13 + PPSV23: all adults >/= 65, or 19-64 with asplenia, immunocompromised,
CSF leaks, cochlear implant, advanced CKD
COPD - ANS-persistent airflow limitation that is usually progressive and associated with
enhanced chronic inflammatory response in the airways and lung to noxious particles or
gases
COPD Diagnosis - ANS-*symptoms compatible with COPD (DOE, cough, sputum)
*spirometry=FEV1/FVC ration <70% plus FEV1 <80% predicted
*no alternative explanation for symptoms
*Alpha-1 antitrypsin deficiency
COPD Stage 1 - ANS-Mild: FEV1/FVC <70%, with or without symptoms
COPD Stage 2 - ANS-Moderate: FEV1/FVC <70%, dyspnea with exertion, with or
without cough and sputum production